Glenzocimab
- CAS No.
- 2101829-58-5
- Chemical Name:
- Glenzocimab
- Synonyms
- ACT017;Glenzocimab;Glenzocimab (anti-GP6);Research Grade Glenzocimab;Research Grade Glenzocimab (DHJ60601)
- CBNumber:
- CB18081129
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 58D9BCH9O0 |
Glenzocimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628787 | ACT017 ≥99.0% | 2101829-58-5 | 1mg | $379 | 2026-06-04 | Buy |
| ChemScene | CS-0628787 | ACT017 ≥99.0% | 2101829-58-5 | 5mg | $986 | 2026-06-04 | Buy |
| ChemScene | CS-0628787 | ACT017 ≥99.0% | 2101829-58-5 | 10mg | $1625 | 2026-06-04 | Buy |
| aablocks | AA02A0VG | Glenzocimab ≥95%(SDS-PAGE&SEC-HPLC) | 2101829-58-5 | 1mg | $576 | 2026-06-02 | Buy |
| aablocks | AA02A0VG | Glenzocimab ≥95%(SDS-PAGE&SEC-HPLC) | 2101829-58-5 | 5mg | $1510 | 2026-06-02 | Buy |
Glenzocimab Chemical Properties, Uses, Production
Uses
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke[1][2].
in vivo
ACT017 (1-8 mg/kg; i.v.) inhibits collagen-induced platelet aggregation in cynomolgus monkeys[2].
| Animal Model: | Cynomolgus monkeys[2] |
| Dosage: | 1-8 mg/kg |
| Administration: | I.v. |
| Result: | Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus. |
References
[1] Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. DOI:10.1161/STROKEAHA.122.039790
[2] Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958. DOI:10.1080/19420862.2017.1336592
Glenzocimab Preparation Products And Raw materials
Raw materials
Preparation Products
Glenzocimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
View Latest Price from Glenzocimab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-21 | Glenzocimab
2101829-58-5
|
$228.00-987.00 | 100% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Glenzocimab
2101829-58-5
- $228.00-987.00
- 100% (SEC-HPLC)
- TargetMol Chemicals Inc.
